Aquestive Therapeutics Files 8-K for Material Agreement

Ticker: AQST · Form: 8-K · Filed: Aug 15, 2025 · CIK: 1398733

Aquestive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form Type8-K
Filed DateAug 15, 2025
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.001, $4.00
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, 8-k, disclosure

Related Tickers: AQST

TL;DR

AQST filed an 8-K for a new material agreement, check for details.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on August 15, 2025, reporting an entry into a material definitive agreement on August 14, 2025. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company, previously known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.

Why It Matters

This 8-K filing indicates a significant new agreement for Aquestive Therapeutics, which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.

Key Numbers

  • 001-38599 — SEC File Number (Identifies the company's filing history with the SEC)
  • 82-3827296 — Commission File Number (Another identifier for the company's filings)

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • MonoSol Rx, Inc. (company) — Former company name
  • August 14, 2025 (date) — Date of earliest event reported
  • August 15, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Warren, NJ (location) — Principal executive offices

FAQ

What is the nature of the material definitive agreement entered into by Aquestive Therapeutics?

The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in this excerpt.

When was the material definitive agreement entered into?

The agreement was entered into on August 14, 2025, as indicated by the 'Date as of change' and 'Date of earliest event reported'.

What other information is included in this 8-K filing?

The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.

What was Aquestive Therapeutics' former company name?

The company's former name was MonoSol Rx, Inc.

Where are Aquestive Therapeutics' principal executive offices located?

The principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.

Filing Stats: 1,264 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2025-08-14 21:37:47

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market
  • $4.00 — Common Stock"), at an offering price of $4.00 per share. The gross proceeds to the C

Filing Documents

01

Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement On August 14, 2025, Aquestive Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company and Leerink Partners LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. , as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten offering of 21,250,000 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at an offering price of $4.00 per share. The gross proceeds to the Company from the offering are expected to be $ 85.0 million, after deducting the underwriting discount and estimated offering expenses payable by the Company. All of the shares of Common Stock in the offering are being sold by the Company. The closing of the offering is expected to occur on August 15 , 2025, subject to customary closing conditions. The Company intends to use the net proceeds received from the offering, together with its existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration approval, and for working capital, capital expenditures and general corporate purposes. Based on the Company's current operating plan, it believes that the net proceeds from the offering, together with its existing cash and cash equivalents, will enable the Company to fund its planned operating expenses and capital expenditures into 2027. The offering is being made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-278498) previously filed with the Securities and Exchange Commission and declared effective on April 23, 2024, and prospectus supplement thereunder. The Underwriting Agreement contains representations, warranti

01

Item 7.01 Regulation FD Disclosure. In connection with investor meetings on August 13, 2025, the Company used the investor presentation furnished hereunder as Exhibit 99.1. On August 14, 2025, the Company issued a press release announcing the pricing of the offering. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. The information included in this Item 7.01 of this Current Report, including the attached Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements Litigation Reform Act of 1995, including, without limitation, statements about the Company's expectations with respect to the completion, timing and size of the offering and the expected amount and use of net proceeds from the offering. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering. Additional factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements are disclosed in the Company's filings with the Securities and Exchange Commission, including in the section captioned "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024. All forward-looking These forward-looking statements should not be relied upon as representing the Company's views as

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated August 14, 2025, by and among Aquestive Therapeutics, Inc. and Leerink Partners LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein 5.1 Opinion of Dechert LLP 23.1 Consent of Dechert LLP (included in Exhibit 5.1) 99.1 Investor Presentation of the Company, dated August 13, 2025 99.2 Press Release of the Company issued on August 14, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 14, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr. Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.